Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies.

PubWeight™: 1.80‹?› | Rank: Top 3%

🔗 View Article (PMID 1972442)

Published in Lancet on June 23, 1990


J Atzpodien1, A Körfer, C R Franks, H Poliwoda, H Kirchner

Author Affiliations

1: Department of Haematology and Oncology, M.H.H. University Medical Center, Hannover, West Germany.

Articles citing this

Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer (2003) 2.18

Survival in renal cell carcinoma-a randomized evaluation of tamoxifen vs interleukin 2, alpha-interferon (leucocyte) and tamoxifen. Br J Cancer (1998) 1.57

IL-2 in combination with IFN- alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br J Cancer (2001) 1.42

Registration of drugs for treating cancer and HIV infection: a plea to carry out phase 3 trials before admission to the market. BMJ (1995) 1.14

Prognostic impact of in vivo soluble cell adhesion molecules in metastatic renal cell carcinoma. Br J Cancer (1999) 1.03

Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG). Br J Cancer (2001) 1.02

Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma. Br J Cancer (1994) 0.96

Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma. Br J Cancer (1998) 0.94

Subcutaneous administration of interleukin 2 and interferon-alpha-2b in advanced renal cell carcinoma: a confirmatory study. Br J Cancer (1995) 0.93

Rapid deterioration in quality of life during interleukin-2- and alpha-interferon-based home therapy of renal cell carcinoma is associated with a good outcome. Br J Cancer (2003) 0.90

Patients with metastatic renal carcinoma candidate for immunotherapy with cytokines. Analysis of a single institution study on 181 patients. Br J Cancer (1993) 0.86

Interleukin-2/interferon-alpha2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br J Cancer (2006) 0.83

A randomized phase II trial of interleukin 2 and interleukin 2-interferon alpha in advanced renal cancer. Br J Cancer (1998) 0.83

Effectiveness of very low doses of immunotherapy in advanced renal cell cancer. Br J Cancer (1997) 0.81

Pharmacokinetics of recombinant human interleukin-2 in advanced renal cell carcinoma patients following subcutaneous application. Br J Clin Pharmacol (1998) 0.79

Intravenous interleukin-2 in patients over 65 with metastatic renal carcinoma. Br J Cancer (1992) 0.79

Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell carcinoma. Br J Cancer (1997) 0.78

Peri-operative modulation of cellular immunity in patients with colorectal cancer. Clin Exp Immunol (1993) 0.77

Treatment of metastatic renal cell carcinoma with subcutaneous interleukin 2: evidence for non-renal clearance of cytokines. Br J Cancer (1997) 0.76

Lobular panniculitis after subcutaneous administration of interleukin-2 (IL-2), and its exacerbation during intravenous therapy with IL-2. Br J Cancer (1992) 0.75

Decrease in cholesterol levels during the immunotherapy of cancer with interleukin-2. Br J Cancer (1991) 0.75

Immunological effects of alternative weekly interferon-alpha-2b and low dose interleukin-2 in patients with cancer. Br J Cancer (1992) 0.75

Immunotherapy for renal carcinoma: theoretical basis and current standard of care. Br J Clin Pharmacol (2000) 0.75

Type 1 cytokine response and treatment outcome of genital HPV lesions. Genitourin Med (1997) 0.75

Articles by these authors

Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature (1982) 3.26

Antiviral effects of recombinant tumour necrosis factor in vitro. Nature (1986) 3.25

The immunobiology of zinc. Immunol Today (1997) 2.93

High incidence of active cytomegalovirus infection among septic patients. Clin Infect Dis (1998) 2.48

Association between clinical disease activity and Epstein-Barr virus reactivation in MS. Neurology (2000) 2.46

Evidence of suppressor cell activity in spleens of mice bearing primary tumors induced by Moloney sarcoma virus. J Exp Med (1974) 2.40

Splenic suppressor macrophages induced in mice by injection of Corynebacterium parvum. J Immunol (1975) 2.13

Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol (2004) 2.07

Interferon-gamma production by Listeria monocytogenes-specific T cells active in cellular antibacterial immunity. Eur J Immunol (1983) 2.06

Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanoma. J Natl Cancer Inst (1996) 1.79

Long-term survival of HeLa tumours in mice treated with antilymphocyte serum. Br J Cancer (1973) 1.69

Does treatment with cimetidine extended beyond initial healing of duodenal ulcer reduce the subsequent relapse rate? Br Med J (Clin Res Ed) (1982) 1.69

Low ferritin levels indicate the need for iron supplementation: strategy to minimize iron-depletion in regular blood donors. Transfus Med (2000) 1.67

Detection and quantification of latently infected B lymphocytes in Epstein-Barr virus-seropositive, healthy individuals by polymerase chain reaction. J Clin Microbiol (1992) 1.66

Single-agent carboplatinum for advanced seminoma. A phase II study. Cancer (1993) 1.63

Inhibition of proliferation of lymphoma cells and T lymphocytes by suppressor cells from spleens of tumor-bearing mice. J Immunol (1975) 1.62

Failure to detect human cytomegalovirus DNA in peripheral blood leukocytes of healthy blood donors by the polymerase chain reaction. Transfusion (1992) 1.60

Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma. J Clin Oncol (1995) 1.58

Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations? Acta Neurol Scand (1988) 1.57

Interferon treatment inhibits onset of herpes simplex virus immediate-early transcription. Virology (1988) 1.55

Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J Urol (1996) 1.55

Two functionally distinct anti-tumor effector cells isolated from primary murine sarcoma virus-induced tumors. J Immunol (1976) 1.53

Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann Oncol (1992) 1.50

Altered cytokine production in the elderly. Mech Ageing Dev (1998) 1.47

Polyclonal immunoglobulin secretion by human B lymphocytes exposed to Epstein-Barr virus in vitro. J Immunol (1979) 1.46

Production of immune interferon by murine T-cell clones from long-term cultures. Nature (1981) 1.45

IL-2 in combination with IFN- alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br J Cancer (2001) 1.42

Production of cytokines in acute schizophrenic psychosis. Biol Psychiatry (1996) 1.41

Neuropsychiatric symptoms during treatment with interleukin-2 and interferon-alpha. Lancet (1993) 1.40

[An interuniversity comparison of the supervision of doctoral candidates--should the promotion procedures be changed?]. Dtsch Med Wochenschr (2000) 1.40

Low-dose subcutaneous recombinant interleukin-2 in advanced human malignancy: a phase II outpatient study. Mol Biother (1990) 1.37

Coincidence of neonatal alloimmune thrombocytopenia and maternal anti-D immunization: case report. Br J Haematol (1998) 1.37

The detection of human cytomegalovirus immediate early antigen in peripheral blood leucocytes. J Immunol Methods (1991) 1.35

Kinetics of the Zn 2+ - stimulation of human peripheral lmphocytes in vitro. Proc Soc Exp Biol Med (1971) 1.34

The influence of naturally occurring heterophilic anti-immunoglobulin antibodies on direct measurement of serum proteins using sandwich ELISAs. J Immunol Methods (2000) 1.34

[Kinetics of serum enzymes in the streptokinase treatment of myocardial infarction]. Klin Wochenschr (1973) 1.33

Identification of herpes simplex virus type 1 (HSV-1) glycoprotein gC as the immunodominant antigen for HSV-1-specific memory cytotoxic T lymphocytes. J Immunol (1985) 1.28

Genetic variability of herpes simplex virus: development of a pathogenic variant during passaging of a nonpathogenic herpes simplex virus type 1 virus strain in mouse brain. J Virol (1983) 1.27

Antiviral activity of tumour necrosis factor. Synergism with interferons and induction of oligo-2',5'-adenylate synthetase. J Gen Virol (1988) 1.26

The effect of sex hormones on peripheral immunity in patients with advanced breast cancer. Clin Oncol (1978) 1.26

Experimental infection of inbred mice with herpes simplex virus type 1. I. Investigation of humoral and cellular immunity and of interferon induction. J Gen Virol (1981) 1.25

Failure to detect antiviral activity in serum and plasma of healthy individuals displaying high activity in ELISA for IFN-alpha and IFN-beta. J Interferon Cytokine Res (1999) 1.24

In vitro mitogenic stimulation of murine spleen cells by herpes simplex virus. J Immunol (1978) 1.24

Replication of herpes simplex virus in human T lymphocytes: characterization of the viral target cell. J Immunol (1984) 1.24

Zinc-altered immune function and cytokine production. J Nutr (2000) 1.22

The effects of general anesthesia on human peripheral immune cell distribution and cytokine production. Clin Immunol Immunopathol (1997) 1.21

Prostaglandin synthesis in spleen cell cultures of mice injected with Corynebacterium parvum. Cell Immunol (1978) 1.20

Human cytomegalovirus replicates in primary human bone marrow cells. J Gen Virol (1986) 1.18

Cytokine production and serum proteins in depression. Scand J Immunol (1995) 1.18

Experimental infection of inbred mice with herpes simplex virus. V. Investigations with a virus strain non-lethal after peripheral infection. J Gen Virol (1982) 1.18

Rapid HLA-DRB1 genotyping by nested PCR amplification. Tissue Antigens (1992) 1.16

Pokeweed mitogen-, concanavalin A-, and phytohemagglutinin-induced development of cytotoxic effector lymphocytes. An evaluation of the mechanisms of T cell-mediated cytotoxicity. J Exp Med (1973) 1.16

The role of interferon in the resistance of C57BL/6 mice to various doses of herpes simplex virus type 1. J Infect Dis (1982) 1.16

Inhibition of the mixed lymphocyte culture by peritoneal exudate cells. Cell Immunol (1976) 1.15

The effect of sex hormones on the growth of HeLa tumour nodules in male and female mice. Br J Cancer (1975) 1.15

Stimulation of chicken lymphocytes in a serum-free medium. Cell Immunol (1972) 1.15

Correlation between clinical response to interleukin 2 therapy and sustained production of tumor necrosis factor. Cancer Res (1990) 1.14

Mycoplasma contamination in human tumor cell lines: effect on interferon induction and susceptibility to natural killing. J Immunol (1981) 1.13

Observations of enzyme elevations in the serum during streptokinase treatment. J Clin Pathol (1972) 1.13

Thrombolytic therapy of recent myocardial infarction. I. Introduction, plan of trial, general clinical results. Ger Med Mon (1966) 1.09

Dysregulation between TH1 and TH2 T cell subpopulations in the elderly. Mech Ageing Dev (1996) 1.08

An X-linked locus influences the amount of circulating interferon induced in the mouse by herpes simplex virus type 1. J Gen Virol (1982) 1.08

A reappraisal of the effector cells mediating mitogen induced cellular cytotoxicity. Cell Immunol (1975) 1.08

Clonal analysis of human T cell activation by the Mycoplasma arthritidis mitogen (MAS). Eur J Immunol (1988) 1.08

[On thrombolytic therapy of a recent myocardial infarct. I. Introduction, treatment plans, general clinical results]. Dtsch Med Wochenschr (1966) 1.08

Cytomegalovirus transcripts in peripheral blood leukocytes of actively infected transplant patients detected by reverse transcription-polymerase chain reaction. J Infect Dis (1993) 1.07

Inflammatory markers in major depression and melancholia. J Affect Disord (2001) 1.07

Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial. Ann Oncol (2008) 1.06

Increased S100B blood levels in unmedicated and treated schizophrenic patients are correlated with negative symptomatology. Mol Psychiatry (2001) 1.05

Inhibition of in vitro lymphoproliferative responses to tumor-associated antigens by suppressor cells from rats bearing progressively growing Gross leukemia virus-induced tumors. Int J Cancer (1975) 1.05

Subcutaneous growth of human tumours in mice. Nature (1973) 1.05

Normalized quantification by real-time PCR of Epstein-Barr virus load in patients at risk for posttransplant lymphoproliferative disorders. J Clin Microbiol (2001) 1.05

Kinetics and organ distribution of allogeneic natural killer lymphocytes transfused into patients suffering from renal cell carcinoma. Stem Cells Dev (2004) 1.04

Protection against herpes simplex virus infection in mice by Corynebacterium parvum. Infect Immun (1977) 1.04

Coincidence of Epstein-Barr virus reactivation, cytomegalovirus infection, and rejection episodes in renal transplant recipients. Transplantation (1995) 1.04

Clinical significance of anti-IFN-alpha antibody titres during interferon therapy. Lancet (1987) 1.04

Stimulation of human peripheral lymphocytes by Zn2+ in vitro. Exp Cell Res (1970) 1.04

Recent progress in the tumor necrosis factor-alpha field. Int Arch Allergy Immunol (1996) 1.03

Prognostic impact of in vivo soluble cell adhesion molecules in metastatic renal cell carcinoma. Br J Cancer (1999) 1.03

A whole-blood technique for testing production of human interferon by leukocytes. J Immunol Methods (1982) 1.03

Human peripheral null lymphocytes. II. Producers of type-1 interferon upon stimulation with tumor cells, Herpes simplex virus and Corynebacterium parvum. Eur J Immunol (1980) 1.02

Mucosal cytokine expression, cellular markers and adhesion molecules in inflammatory bowel disease. Eur J Gastroenterol Hepatol (1999) 1.02

Experimental infection of inbred mice with herpes simplex virus. II. Interferon production and activation of natural killer cells in the peritoneal exudate. J Gen Virol (1981) 1.02

Production of immune interferon is regulated by more than T cell subset: Lyt-1,2,3 and Qat-5 phenotypes of murine T lymphocytes involved in IFN-gamma production in primary and secondary mixed lymphocyte reaction. Eur J Immunol (1982) 1.02

A comparison of the toxicity and efficacy of cisplatin and carboplatin in advanced ovarian cancer. The Swons Gynaecological Cancer Group. Acta Oncol (1989) 1.02

Production of an antiviral factor by murine spleen cells after treatment with Corynebacterium parvum. Cell Immunol (1977) 1.02

Febrile and allergic transfusion reactions after the transfusion of white cell-poor platelet preparations. Transfusion (2000) 1.02

Cytokine production after helium-neon laser irradiation in cultures of human peripheral blood mononuclear cells. J Photochem Photobiol B (1992) 1.01

Transplantation of allogeneic CD34+ blood cells. Blood (1996) 1.01

Biochemotherapy of advanced metastatic renal-cell carcinoma: results of the combination of interleukin-2, alpha-interferon, 5-fluorouracil, vinblastine, and 13-cis-retinoic acid. World J Urol (1995) 1.01

Elevated plasma levels of S-100b protein in schizophrenic patients. Biol Psychiatry (1999) 1.01

A human whole-blood assay for analysis of T-cell function by quantification of cytokine mRNA. Scand J Immunol (1999) 1.01

Immunobiology of human papillomavirus infection. Prog Med Virol (1986) 1.00

Interleukin 2 therapy in cancer: identification of responders. Br J Cancer (1992) 1.00

The production of a monocyte chemotactic factor by agammaglobulinemic chicken spleen cells. J Immunol (1972) 1.00

Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer. J Clin Oncol (1999) 1.00

Production of colony-stimulating factors by Hodgkin cell lines. Int J Cancer (1983) 1.00